EZH2 and ovarian carcinoma: In ovarian cancer models, EZH2-mediated histone methylation and DNA methyltransferase programmed death-ligand 1(PD-L1)-mediated DNA methylation inhibit chemokine CXCL9 and CXCL10 expression, promoting tumor aggressiveness.